Hepatitis Monthly

Published by: Kowsar

Telaprevir Experience From Turkey

Suheyla Komur 1 , * , Behice Kurtaran 1 , Ayse Seza Inal 1 , Husnu Pullukcu 2 , Aslihan Ulu 1 , Ferit Kuscu 3 , Tansu Yamazhan 2 , Yesim Tasova 1 and Hasan Salih Zeki Aksu 1
Authors Information
1 Department of Infectious Diseases, Cukurova University, Adana, Turkey
2 Department of Infectious Diseases, Ege University, Izmir, Turkey
3 Numune Training and Research Hospital, Adana, Turkey
Article information
  • Hepatitis Monthly: February 28, 2015, 15 (2); e25639
  • Published Online: February 18, 2015
  • Article Type: Brief Report
  • Received: November 27, 2014
  • Revised: January 8, 2015
  • Accepted: January 22, 2015
  • DOI: 10.5812/hepatmon.25639

To Cite: Komur S, Kurtaran B, Seza Inal A, Pullukcu H, Ulu A, et al. Telaprevir Experience From Turkey, Hepat Mon. 2015 ; 15(2):e25639. doi: 10.5812/hepatmon.25639.

Abstract
Copyright © 2015, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Acknowledgements
Footnote
References
  • 1. Lavanchy D. The global burden of hepatitis C. Liver Int. 2009; 29 Suppl 1: 74-81[DOI][PubMed]
  • 2. Alter HJ, Seeff LB. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis. 2000; 20(1): 17-35[PubMed]
  • 3. European Association for the Study of the L. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2011; 55(2): 245-64[DOI][PubMed]
  • 4. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB, American Association for Study of Liver D. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011; 54(4): 1433-44[DOI][PubMed]
  • 5. Park C, Jiang S, Lawson KA. Efficacy and safety of telaprevir and boceprevir in patients with hepatitis C genotype 1: a meta-analysis. J Clin Pharm Ther. 2014; 39(1): 14-24[DOI][PubMed]
  • 6. McHutchison JG, Manns MP, Muir AJ, Terrault NA, Jacobson IM, Afdhal NH, et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med. 2010; 362(14): 1292-303[DOI][PubMed]
  • 7. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med. 2011; 364(25): 2417-28[DOI][PubMed]
  • 8. Akinci E, ÜNal Kayaaslan B, Tanrici BaŞBuĞ A, Sırrı Eren S, ÖNgÜRÜ P, Bodur H. Genotip 1b Kronik Hepatit C Hastalarında Kalıcı Virolojik Yanıtın Değerlendirilmesi. Viral Hepatit Dergisi. 2013; 19(2): 80-4[DOI]
  • 9. Shimada N, Tsubota A, Atsukawa M, Abe H, Ide T, Takaguchi K, et al. A 48-week telaprevir-based triple combination therapy improves sustained virological response rate in previous non-responders to peginterferon and ribavirin with genotype 1b chronic hepatitis C: A multicenter study. Hepatol Res. 2014; 44(14)-96[DOI][PubMed]
  • 10. Chopra A, Klein PL, Drinnan T, Lee SS. How to optimize HCV therapy in genotype 1 patients: management of side-effects. Liver Int. 2013; 33 Suppl 1: 30-4[DOI][PubMed]
  • 11. Cacoub P, Bourliere M, Lubbe J, Dupin N, Buggisch P, Dusheiko G, et al. Dermatological side effects of hepatitis C and its treatment: patient management in the era of direct-acting antivirals. J Hepatol. 2012; 56(2): 455-63[DOI][PubMed]
  • 12. McHutchison JG, Everson GT, Gordon SC, Jacobson IM, Sulkowski M, Kauffman R, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med. 2009; 360(18): 1827-38[DOI][PubMed]
  • 13. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011; 364(25): 2405-16[DOI][PubMed]
  • 14. Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, Everson GT, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med. 2011; 365(11): 1014-24[DOI][PubMed]
  • 15. Maasoumy B, Port K, Markova AA, Serrano BC, Rogalska-Taranta M, Sollik L, et al. Eligibility and safety of triple therapy for hepatitis C: lessons learned from the first experience in a real world setting. PLoS One. 2013; 8(2)[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments